Tonix Pharmaceuticals Holding Corp [TNXP] stock prices are up 2.57% to $0.38 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TNXP shares have gain 10.11% over the last week, with a monthly amount glided 10.20%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 29, February 2024, Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia. In a post published today on Yahoo Finance, Additional data from recently reported positive Phase 3 RESILIENT trial will be presented.
From an analyst’s perspective:
Previously, ROTH Capital upgraded its rating to Buy on April 18, 2019, and kept the price target unchanged to $4. On August 18, 2017, upgrade upgraded it’s rating to Buy but maintained its price target of $6 on the stock. ROTH Capital downgraded its rating to a Neutral. Oppenheimer reiterated its recommendation of a Outperform and reduced its price target to $10 on February 17, 2016. In a note dated June 12, 2015, Oppenheimer initiated an Outperform rating and provided a target price of $18 on this stock.
The stock price of Tonix Pharmaceuticals Holding Corp [TNXP] has been fluctuating between $0.26 and $4.94 over the past year. Tonix Pharmaceuticals Holding Corp [NASDAQ: TNXP] shares were valued at $0.38 at the most recent close of the market.
Analyzing the TNXP fundamentals
Gross Profit Margin for this corporation currently stands at 0.13% with Operating Profit Margin at -3.27%, Pretax Profit Margin comes in at -3.19%, and Net Profit Margin reading is -3.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.9, Equity is -0.79 and Total Capital is -1.02. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3595 points at the first support level, and at 0.3398 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3903, and for the 2nd resistance point, it is at 0.4014.
Tonix Pharmaceuticals Holding Corp [TNXP] reported earnings per share of -$1.83 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.49/share, meaning a difference of -$0.34 and a surprise factor of -22.80%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$2.68 per share as compared to estimates of -$2.75 per share, a difference of $0.07 representing a surprise of 2.50%.
Ratios To Look Out For
It’s worth pointing out that Tonix Pharmaceuticals Holding Corp [NASDAQ:TNXP]’s Current Ratio is 1.77. Further, the Quick Ratio stands at 1.02, while the Cash Ratio is 0.39. Considering the valuation of this stock, the price to sales ratio is 7.68, the price to book ratio is 0.06.
